Lantern Pharma Gains FDA Support for HARMONIC Trial Amendments in Never-Smoker Lung Cancer

Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration (FDA) raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma. The company stated that the FDA's written response to its Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.

The HARMONIC trial is a randomized, double-blind, placebo-controlled study assessing LP-300 in combination with standard chemotherapy versus placebo plus chemotherapy in never-smoker patients with relapsed advanced lung adenocarcinoma after tyrosine kinase inhibitor (TKI) treatment. The FDA's support for the amendments, which refine the patient population to those with specific EGFR mutations, could accelerate enrollment and strengthen the evidence base for a potential future new drug application. Lantern Pharma's precision oncology approach leverages its proprietary RADR platform to identify patient subgroups most likely to benefit from its therapies.

LP-300 is a cisplatin/ethacraplatin analog designed to overcome resistance mechanisms in certain tumor types. The company's pipeline also includes LP-184 for solid tumors and pediatric CNS cancers, and LP-284 for hematologic malignancies. Additionally, Lantern recently launched withZeta.ai, a multi-agentic AI co-scientist platform available as a subscription service for the biomedical community, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.

For more details on the announcement, visit the full press release at https://ibn.fm/Rxklm. Investors seeking updates on LTRN can access the company's newsroom at https://ibn.fm/LTRN.